Anthem Biosciences Reports Q1 FY27 Results: Revenue Stands at ₹4,182 Mn as EBITDA Reaches ₹1,755 Mn
Anthem Biosciences Limited has announced its unaudited Consolidated Financial Results for the quarter ended June 30, 2026. The company reported a Consolidated Revenue from Operations of ₹4,182 Mn and an Earnings Before Interest, Depreciation, and Amortisation (EBITDA) of ₹1,755 Mn, resulting in 39.6% EBITDA margins. Profit After Tax (PAT) was recorded at ₹1,199 Mn, achieving PAT margins of 27.1%.The results reflect the company's status as an innovation-driven Contract Research, Development and Manufacturing Organization (CRDMO). The Q1FY27 performance shows a decline in revenue compared to previous periods, with Revenue from Operations standing at ₹4,182 Mn against ₹5,402 Mn in Q1FY26.
Q1 FY27 Financial Performance Snapshot
The financial highlights for the quarter include:| Particulars (₹ Mn) | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Revenue from Operations | 4,182 | 5,402 | -22.6% |
| CRDMO Business | 3,408 | 4,527 | -24.7% |
| Specialty Ingredients | 774 | 875 | -11.5% |
| Total Revenues | 4,431 | 5,630 | -21.3% |
| EBITDA | 1,755 | 2,143 | -18.1% |
| Profit After Tax (PAT) | 1,199 | 1,358 | 11.7% |
The company’s revenue stream comprises the CRDMO business, which contributed ₹3,408 Mn, and Specialty Ingredients, which generated ₹774 Mn. Other Income accounted for ₹249 Mn in Q1FY27, up from ₹228 Mn in Q1FY26.
The key financial figures for the quarter are as follows:
- Consolidated Revenue from Operations: ₹4,182 Mn
- EBITDA: ₹1,755 Mn (with a 39.6% margin)
- Profit Before Tax (PBT): ₹1,446 Mn
- Profit After Tax (PAT): ₹1,199 Mn (with a 27.1% margin)
Management provided commentary on the quarterly performance. Ajay Bhardwaj, Chairman, MD and CEO of Anthem Biosciences Limited, stated that the Q1FY27 results reflect shifts in delivery timings to key customers. He added that underlying demand remains strong and that the company is strategically positioned to capture momentum as a higher concentration of scheduled deliveries is anticipated in the latter half of the year.
Mr. Bhardwaj also noted that margin performance showed improvement year-on-year across both EBITDA and PAT margins, attributing this stability to disciplined focus on cost efficiencies, yield optimization, and employee productivity.
Anthem Biosciences Limited has scheduled an earnings call for July 22, 2026, at 11:30 am (IST) to discuss the company’s financial and business performance for the quarter.
ANTHEM Stock Price Movement
Anthem Biosciences Limited shares today edged higher to settle at ₹791.55, closing up 0.31%. The stock saw significant activity, trading a total of 648,680 shares during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.